Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.
Clinical-stage biotech developing LB-102, an oral antipsychotic drug candidate for schizophrenia.
Has no product revenue and pays for trials by selling shares, so each trial result affects how much capital it can raise. LB-102 is a modified form of amisulpride, an antipsychotic sold in Europe but never approved in the US, which gives it a safety record from abroad.
Moat: none (IP / patents). Pre-commercial; competes in a crowded antipsychotic market against established generics and branded drugs.
Headquarters: New York, New York, US · Founded: 2019 · Employees: 27
Size LB Pharmaceuticals (LBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.30B, the 2074th largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.06 on 18 Nov 2026.
Performance Over six months the shares gained 42.9%, against -17.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Short interest Short interest is 19.1% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$388,000 | -$321,000 | -$91,000 | -$4,000 | -$2,000 |
| EBITDA | -$152M | -$30.1M | -$64.7M | -$11.4M | -$2.81M |
| Net income | -$141M | -$25.2M | -$63.1M | -$6.28M | -$14.3M |
| Free cash flow | -$144M | -$35.3M | -$53.8M | -$12.1M | -$2.73M |
| Capital expenditure | $505,000 | $52,000 | $769,000 | $25,000 | $0 |
| Total debt | $5.16M | $3.57M | $3.70M | $0 | $24.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| LB Pharmaceuticals LBRX | $1.30B | +43% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Alkermes Public ALKS | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LBRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.3% | -4.8% | 8th highest of 20 |
| 6-month return | +42.9% | -17.3% | 2nd highest of 20 |
| Distance from 52-week high | -20.1% | -37.5% | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |